Agenus Inc. (AGEN): Price and Financial Metrics

Agenus Inc. (AGEN): $13.62

1.27 (+10.28%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add AGEN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#84 of 360

in industry

AGEN Price/Volume Stats

Current price $13.62 52-week high $42.60
Prev. close $12.35 52-week low $4.78
Day low $12.35 Volume 695,400
Day high $14.18 Avg. volume 682,195
50-day MA $10.25 Dividend yield N/A
200-day MA $15.93 Market Cap 286.01M

AGEN Stock Price Chart Interactive Chart >


Agenus Inc. (AGEN) Company Bio


Agenus Inc. engages in discovering and developing innovative treatments for patients with cancer and other diseases. The company was founded in 1994 and is based in Lexington, Massachusetts.


AGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

AGEN Latest Social Stream


Loading social stream, please wait...

View Full AGEN Social Stream

Latest AGEN News From Around the Web

Below are the latest news stories about AGENUS INC that investors may wish to consider to help them evaluate AGEN as an investment opportunity.

Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag

Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.

Yahoo | December 26, 2023

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

These two biotech stocks could be poised for a trend reversal.

Yahoo | December 24, 2023

GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate

GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.

Yahoo | December 21, 2023

Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024

LEXINGTON, Mass., December 20, 2023--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that data from an investigator sponsored trial (IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune activator) in combination with balstilimab (BAL, PD-1 antibody) in neoadjuvant colorectal cancer (CRC) will be presented at the upcoming ASCO-GI Meeting, to be held January 18 – 20, 2024 in San Francisco

Yahoo | December 20, 2023

Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up

Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.

Yahoo | December 13, 2023

Read More 'AGEN' Stories Here

AGEN Price Returns

1-mo 16.51%
3-mo -12.45%
6-mo -2.80%
1-year -53.03%
3-year -84.01%
5-year -75.50%
YTD -17.74%
2023 -65.50%
2022 -25.47%
2021 1.26%
2020 -21.87%
2019 71.01%

Continue Researching AGEN

Here are a few links from around the web to help you further your research on Agenus Inc's stock as an investment opportunity:

Agenus Inc (AGEN) Stock Price | Nasdaq
Agenus Inc (AGEN) Stock Quote, History and News - Yahoo Finance
Agenus Inc (AGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!